The transdermal contraceptive patch: an updated review of the literature
Katharine O'Connell1, Ronald T Burkman
1Columbia University College of Physicians and Surgeons, New York, New York 10032, USA. ko2032@columbia.edu
Abstract:
The transdermal contraceptive patch which contains ethinyl estradiol and norelgestromin has an efficacy similar to current oral contraceptives (OCs). The major advantages include transdermal application and maintenance of adequate hormonal levels for at least 7 days. Side effects are similar to OC except for breast tenderness in the first 2 months of use and skin irritation at the application site. Although concern has been raised about a possible increased risk of venous thromboembolism, current available data comparing the patch to a norgestimate-containing OC ranges from no increase in risk to a 2.4-fold increase.
More Related Videos
09:04Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
08:26Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices
Published on: January 30, 2026
Related Concept Videos
Transdermal Drug Delivery Systems
Intrauterine Drug Delivery Systems
Birth Control Methods
Modified-Release Drug Delivery Systems: Overview
Oral Drug Delivery Systems: Continuous-Release Systems
Patch Clamp
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...
